A phenotypic change of smooth muscle cells (SMCs) is considered to be critical in the pathogenesis of atherosclerotic lesions such as coronary artery disease (CAD). Mrf-2/ ARID5B, a member of the AT-rich interaction domain family of transcription factors, is highly expressed in the cardiovascular system and is believed to play essential roles in the phenotypic change of SMCs through its regulation of SMC differentiation. In addition, recent studies on gene-engineered mice suggested that this transcriptional factor is involved in obesity and adipogenesis, which are critical aspects for the pathogenesis of atherosclerosis. Thus, we hypothesized that genetic variations of the Mrf-2 gene might be associated with susceptibility to CAD.
Single nucleotide polymorphisms (SNPs) are the most common genetic variations in the genome and some are reported to influence susceptibility to atherosclerosis, plaque destabilization, and thrombosis, all of which are fundamental aspects of CAD. 2, 3) Vascular smooth muscle is a critical cellular constituent of the blood vessel wall. Phenotypic changes in smooth muscle cells (SMCs) are considered to be critical in the pathogenesis of atherosclerotic lesions such as coronary artery disease (CAD). Our group previously investigated the mechanism of a phenotypic change by establishing an in vitro system in which a pluripotent neural crest cell line (MONC-1) can be induced to differentiate into SMCs. By using a differential mRNA display, we isolated a partial cDNA fragment of Mrf-2 (modulator recognition factor) as one of the genes robustly induced during the differentiation progress. Our group was the first to clone the full length of Mrf-2 and reveal the existence of at least two isoforms (α and β) which differ in the N-terminus but share a common DNA-binding domain. 4) Mrf-2, which is also called as ARID5B or Desrt, is a member of the AT-rich interaction domain (ARID) family of transcription factors. The ARID defines a highly conserved sequence specific DNA binding domain and has been identified in proteins of yeast, Drosophila, and mammals. [5] [6] [7] ARID-encoding genes are involved in a variety of biological processes including embryonic development, tissue specific gene expression, proliferation control, and chromatin remodeling. [7] [8] [9] [10] [11] [12] We reported Mrf-2 as a nuclear protein, and its mRNA was highly expressed in the aorta, heart and lung. 4) We also demonstrated that Mrf-2 might also bind to the CArG box, a cis-acting element, which was reported to regulate the expression of many smooth muscle cell specific genes, including smooth muscle cell α-actin and SM 22α. In addition, overexpression of Mrf-2 in 3T3 fibroblast cells induced smooth muscle marker genes and retarded cell proliferation. These results suggested that Mrf-2 might be a potent key regulator for SMC phenotypic change via its regulation of SMC differentiation.
On the other hand, it was reported that targeted disruption of the Mrf-2 gene in mice caused growth retardation and significant reductions in lipid accumulation and weight gain in postnatal and adult life. 8, 13, 14) These observations sug- gested that Mrf-2 might also play important roles in adipogenesis and obesity, which are also critical aspects for the pathogenesis of atherosclerosis. Taking together, we therefore hypothesized genetic variations in the Mrf-2 gene may predispose humans to CAD. The aim of the present study was to confirm whether genetic variations of the Mrf-2 gene are associated with susceptibility to CAD.
METHODS
Subject characteristics: This study was approved by the institutional ethics committee of the University of Tokyo, and written informed consent was obtained from all participants.
To examine the associations between Mrf-2 SNPs and susceptibility to CAD, we recruited 475 CAD patients (372 men and 103 women, aged 65.3 ± 8.6 years old) and 310 control subjects (173 men and 137 women, aged 68.1 ± 9.8 years old) as the study population. The CAD patients were consecutively enrolled from the Department of Cardiovascular Medicine of the University of Tokyo Hospital, and the control subjects were recruited consecutively from the Institute for Adult Diseases Asahi Life Foundation, which is located close to the University of Tokyo Hospital. All subjects were of Japanese ancestry and were not firstor second-degree relatives. All female participants were postmenopausal.
The patients with CAD were enrolled from October 1999 to March 2002 and were diagnosed when at least one of the 3 major coronary vessels had more than 50% narrowing on the basis of coronary angiography. The control subjects were recruited in 2000 based on having a normal ECG pattern and having no medical history of coronary artery disease or stroke in the monthly follow-up or health check-up program at the outpatient clinic of the Institute for Adult Diseases Asahi Life Foundation Hospital, Tokyo. The control subjects who had two or more coronary risk factors (DM, hypertension (HT), hypercholesterolemia, smoking) or had a history of chest pain were further evaluated using the Master or Treadmill exercise test, and those who had an ECG abnormality in the additional testing were excluded.
At the point of enrollment, the baseline profiles of both the CAD patients and control subjects were collected, and past medical history and smoking habits were obtained from all study participants. HT was diagnosed according to World Health Organization criteria. Hypercholesterolemia was diagnosed when total plasma cholesterol levels were > 220 mg/dL or when a subject was already being treated with lipid-lowering medication. DM in the CAD group and control group was diagnosed based on HbA1c > 6.5% or FBS ≥ 126 mg/dL. Fasting venous blood samples were drawn for biochemical and genetic analysis. Venous blood samples were collected in tubes containing Na2EDTA and applied to genomic DNA extracting columns (Genomix kit, Talent) according to the manufacturer's protocol.
The SNPs were identified based on the sequences reported in the JSNPs (Japanese Single Nucleotide Polymorphisms) database (http://snp.ims.u-tokyo. ac.jp/index_ja.html) or the NCBI GeneBank database (http://www.ncbi.nih.gov/ index.html). No exon SNP of Mrf-2 was reported in the above databases for the Japanese population, therefore, 11 intron SNPs which covered the whole length of the Mrf-2 gene were almost equally selected from the public databases to detect the associations between genetic variations of Mrf-2 and CAD.
Two JSNPs (nomenclatures of SNP8, SNP11 represent JSNPs 025551 and 025550, respectively) as well as exon 3, exon 4 and their exon-intron boundaries were genotyped by direct sequencing as described in detail previously. 15) Briefly, PCR was performed under standard conditions and the sequencing reactions were performed using a BigDye terminator kit (Applied Biosystems, Foster City, CA), and resolved using an ABI 3700 automated DNA sequencer (Applied Biosystems). The results were integrated using a Sequencher (Gene Codes Corporation, Ann Arbor, MI) and individual SNPs were manually genotyped. Ambiguous base callings were eliminated from further analysis. The primer sequences are available from the authors.
Meanwhile, nine SNPs of the Mrf-2 gene from the public GeneBank database (nomenclatures of SNP1, SNP2, SNP3, SNP4, SNP5, SNP6, SNP7, SNP9 and SNP10 represent rs6415872, rs10821929, rs7901348, rs2893880, rs10740055, rs7087507, rs10761600, rs12357548 and rs10761604, respectively) were selected and genotyped using a MassARRAY system. When using the MassARRAY system, primer extension products were analyzed by chip based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) following PCR amplification as described in detail previously. 16) Statistical analysis: Continuous parameters such as age, body mass index (BMI), total cholesterol (T-chol), high density cholesterol (HDL), and triglycerides (TG) are presented as the mean ± SD and were compared using Student's t test, while characteristics such as sex, HT, hyperlipidemia (HL), DM, and smoking are given as proportions of the entire samples and were compared using the chi-square (χ 2 ) test. The genotype and allele association for each SNP and CAD were tested using the χ 2 test with 2 and 1 degree (s) of freedom. The odds ratios and 95% CI, with adjustment for classical risk factors of CAD, were calculated by multiple logistic regression analysis. The differences among more than 2 average values were statistically tested using one-way ANOVA. The statistical analyses, except for the linkage disequilibrium and haplotype estimation, were performed using The statistical significance level was corrected for multiple testing, and we took potential overestimation into account when evaluating the most statistically significant value among those tested under different models. A two-tailed value of P < 0.05 was considered to be significant unless otherwise indicated. Haplotype analysis: To examine the pair-wise linkage disequilibrium (LD) structure, linkage disequilibrium coefficients (D') and r 2 between the SNPs and haplotype frequencies were estimated via the method of maximum likelihood from two-locus genotype data using the EM algorithm under the assumption of HardyWeinberg equilibrium. 17, 18) For the estimation of haplotype frequencies, we selected one of the SNPs as a tagging SNP from every set of SNPs with r 2 > 0.80. All haplotypes were jointly tested for association with disease status by performing a 2 x n χ 2 test of independence in a permutation procedure, where "n" indicates the number of haplotypes with a frequency > 0.2.
The above calculations were carried out using SNPAlyze v5.1 standard software (Dynacom, Yokohama, Japan). We considered a P < 0.05 to be statistically significant.
RESULTS

Baseline characteristics of the CAD and control populations:
The baseline characteristics of the CAD patients and the control subjects are shown in Table I . < 0.0001* < 0.0001* < 0.0001* < 0.016* < 0.0001* < 0.0001* < 0.0001* Continuous parameters such as age, BMI, T-chol, HDL, and TG are presented as the mean ± SD and were compared using Student's t test. Characteristics such as sex, HT, HL, DM, and smoking are presented as proportions of the entire sample and were compared using the χ Baseline characteristics including age of the CAD patients were calculated at the point of enrollment when patients underwent the coronary angiography. For the control subjects, ages and other clinical characteristics were adopted at the enrollment point in 2000. As indicated, the patients in the CAD group had more conventional risk factors such as being male, smoking, HT, hypercholesterolemia, and DM in comparison to the control subjects. The average age of the control subjects was older than that of the patients with CAD. Associations between Mrf-2 SNPs and CAD: We identified a total of 17 candidate SNPs composing at least 4 haplotype blocks which covered almost the full length of the Mrf-2 gene as shown in Figure 1 . All polymorphisms were in accordance with Hardy-Weinberg equilibrium both in the CAD and control groups with each minor allele frequency > 5%. The allele and genotypic frequencies of each SNP are shown in Table II and  Table III . The distributions of G-allele in SNP4 (rs2893880) and G-allele in SNP6 (rs7087507) were more frequent in the control group than in the CAD group, and G allele in SNP6 was significantly more prevalent in the control subjects (P = 0.041) (Table II) . We also detected statistically significant differences for the genotype distribution of SNP4 (rs2893880) and SNP6 (rs7087507) for both the dominant model (P = 0.0002 and 0.0058, respectively) and the codominant model (P = 0.0005 and 0.022, respectively), and for the codominant model (P = 0.050) of SNP5, in the comparison of the CAD group and the control group (Table III) . Linkage disequilibrium between Mrf-2 SNPs and CAD: Linkage disequilibrium (LD) was estimated between pairs of SNPs by using an absolute value of D' (|D'|). There was almost complete linkage disequilibrium among SNP4 (rs2893880), SNP5 (rs10740055), SNP6 (rs7087507), and SNP7 (rs10761600). The LD of the above four SNPs covered over 60 kb of the Mrf-2 gene and constituted 1 haplotype block ( Figure 2) .
We then performed haplotype analysis, which is considered to be a more useful method for detecting associations than the assessment of individual SNPs. Seven major combinations (with a frequency > 2% for the entire sample) of the haplotype block consisting of SNP4, SNP5, SNP6, and SNP7 are shown in Table  IV . Haplotype case-control analysis revealed a significant association between CAD and the haplotype G-C-G-A (SNP4-5-6-7) with a minor G in SNP4, a major C in SNP5, a minor G in SNP6, and a major A in SNP7 (P = 0.049). This association was consistent with the observations that GG genotype for SNP4 and GG for SNP6 were negatively associated with susceptibility to CAD.
Logistic regression analysis for the associations of Mrf-2 SNPs with CAD:
The CAD group showed more conventional confounding risk factors. In order to Table IV . Haplotype Analysis for Mrf-2 SNPs and CAD Seven major haplotypes were detected for SNP4 to SNP7. The G-C-G-A haplotype is negatively associated with susceptibility to CAD. * indicates statistical significance. This association is relevant to the fact that the GG (SNP4) and GG (SNP6) are negatively associated with susceptibility to and severity of CAD.
Frequency of Major Haplotypes
eliminate these confounding influences on the presence of CAD, logistic regression analysis was performed for the four SNPs in the risk haplotype block. After adjusting for confounding conventional risk factors such as sex, age, BMI, HT, HL, DM, and smoking, subjects with GG genotype for SNP4 and GG genotype for SNP6 were still at decreased risk for CAD compared with those having Callele for SNP4 and A-allele for SNP6 (P = 0.0040, OR: 2.20, 95%CI: 1.29-3.77 and P = 0.029, OR: 1.82, 95%CI: 1.07-3.12, respectively) ( Table V) .
Tendency of associations between Mrf-2 SNPs and severity of CAD: To evaluate whether Mrf-2 SNPs were associated with the severity of CAD, individuals in the CAD group who had previously undergone coronary artery bypass graft surgery Odds ratios (OR) were calculated using three genetic models. CC+CG/GG and AA+AG/GG are dominant models for SNP4 and SNP6, respectively. OR for each SNP was adjusted simultaneously for sex, age, BMI HT, HL, smoking, and DM. * indicates statistical significance. SNP4 and SNP6 were indicated to be potential independent predictors for susceptibility to CAD after eliminating confounding factors.
(CABG) or percutaneous coronary intervention (PCI) were excluded, and only the patients who underwent a coronary arteriogram for the first time without revascularization were selected for this analysis.
The associations between genotypes of Mrf-2 and the modified Gensini score, 19, 20) which is an index of coronary atherosclerosis severity and is computed by assigning the severity score to each coronary stenosis according to the degree of luminal narrowing and its geographic importance, were investigated. Although the differences among Mrf-2 polymorphisms and severity of CAD did not reach statistical significance, individuals with GG genotype for SNP4 and GG for SNP6 had lower Gensini scores, which was relevant to the correlations that these SNPs were negatively associated with susceptibility to CAD (Figure 3) . No genetic variations were found in exon3 and exon4: Exon 3 is the only exon included in the haplotype block consisting of SNP4-6, and exon 4 is located close to SNP6, therefore, we screened exon3 (226 bp), exon4 (231 bp) and their exonintron boundaries to investigate whether there was functional SNP in these exon regions by comparing sequences of 100 randomly chosen samples of CAD subjects. No SNP was found in these regions.
DISCUSSION
In the present study, we evaluated whether the polymorphisms of the Mrf-2 gene were associated with susceptibility to CAD. We first demonstrated that genetic variations of Mrf-2 in SNP4 (rs2893880) and SNP6 (rs7087507) themselves and in the haplotype block, consisting of SNP4 (rs2893880), SNP5 (rs10740055), SNP6 (rs7087507), and SNP7 (rs10761600) were significantly associated with susceptibility to CAD. Carrying G for SNP4, C for SNP5, G for SNP6, and A for SNP7 was much more likely to play protective roles against CAD.
It is well accepted that the pathogenesis of CAD is multi-factorial. In addition to the conventional coronary risk factors, other factors such as vasoconstriction, 21) and platelet function 22, 23) are also well established. Furthermore, studies have indicated a greater genetic risk in monozygotic twins compared with dizygotic ones, and adoption studies showed evidence that much of the excess risk was genetic rather than environmental for CAD. 24, 25) A number of initial studies attempted to address the possibility that polymorphisms at various candidate genes might be associated with the pathogenesis of CAD and some concluded there was a significant association between them. For example, polymorphisms in renin-angiotensin system gene polymorphisms (angiotensin-type receptor genes, angiotensin II converting enzyme genes) are well known to be associated with hypertension, 26) CAD [27] [28] [29] [30] [31] and MI, [32] [33] [34] though dissenting opinions still exist.
In the case of transcriptional factors, only a few of them were concluded to be associated with the presence of CAD. Within them, controversial data of associations such as the findings between mutations in the myocyte enhancer factor (MEF) gene and the presence of myocardial infarction (MI) have been reported. [35] [36] [37] [38] The contribution of genetic polymorphisms to the pathogenesis of CAD still remains to be definitively established. Our findings provided the first evidence for disease relevance of the polymorphisms of a novel transcription factor, Mrf-2. Some genetic polymorphisms have a direct effect on the occurrence or development of a disease, whereas others have a modifying effect. We previously reported the full length of the Mrf-2 gene consisting of 11 exons and including two nonoverlapped isoforms. The two isoforms differ at the 5' end and share the same sequence from exon5. Exon 1α (specific for Mrf-2α ), together with exon5-10 constitute the shorter isoform named Mrf-2α whose open reading frame was 2835 bp, and exon 1-10 constitute the longer one named Mrf-2β whose open reading frame was 3564 bp. SNPs involved in this study were located in the second and third intron regions of the Mrf-2β gene, and no coding SNP was observed in exon3 caught in the 4 disease associated SNPs and exon4, therefore, these findings suggest the intronic polymorphisms in the Mrf-2β gene are much more likely to have a modifying effect by influencing the expression level of Mrf-2 by themselves or by other unknown causative genetic variations located within or nearby the haplotype block. Since the two isoforms conserve the same sequences from exon5 and the Mrf-2 α specific exon located between exon 4 and exon 5, there are 2 possibilities: one could be that these intronic SNPs of Mrf-2β might be related to probable variations in the promoter region of the Mrf-2α specific exon, as yet unidentified; the other is that they might also regulate the upstream promoter of Mrf-2β as these SNPs are located in the second and third intron region, and by which influence the Mrf-2 expression level and regulate its function. In addition, Mrf-2 is a gene of approximately 200 kb, and the haplotype block containing the disease associated SNPs is located in the mid portion of the Mrf-2 gene, which excluded the possibility that other nearby genes were functionally causative concerning the associations between the Mrf-2 variations and susceptibility to CAD in the present study.
The Mrf-2 SNPs exhibited a tendency to be associated with the severity of CAD with GG genotype for SNP4 and GG genotype for SNP6 had slightly lower Gensini scores. However, these findings did not reach statistical significance. One probable reason might be a reduced statistical power due to the small available sample size because only the CAD patients who underwent coronary arteriogram for the first time without revascularization were selected for this analysis. Individuals who had previously undergone CABG or PCI were excluded, which also indicated another possibility that the reduced statistical power was due to the fact that the more serious patients were excluded from this analysis.
Within the population studied, the definition of CAD was based on coronary angiography, while the control subjects were defined on the basis of having a normal ECG pattern and having no medical history of coronary artery disease or stroke. It remained a possibility that the control group might not be completely free from significant coronary atherosclerosis. However, if it were not for the ethics reason, we would have obtained much clearer results by performing coronary angiography in the control group to exclude the subjects with more than 50% narrowing. Therefore, the results on the associations of Mrf-2 SNPs with CAD in the present study were considered to be reliable.
The positive disease associations were adjusted by performing logistic regression analysis to eliminate conventional confounding risk factors. The significant differences that remained indicated genetic variations of the Mrf-2 may contribute risk to CAD independent from traditional coronary risk factors. Within the studied population, assessments on Mrf-2 variations and each of the traditional coronary risk factors revealed weak associations of Mrf-2 SNPs with DM and BMI. However, statistical significance was not attained after multiple analysis, which might be a result of 1) reduced statistical power due to the small available investigating sample size; and 2) the definition of DM for the CAD and its control groups was based on only one time FBS level or HbA1c value, which was inadequate for obtaining more reliable results. Thus, the possibility that they are associated cannot be excluded, and this should be confirmed in future studies.
At present, although we could not provide definite evidence to elucidate the mechanisms of how the Mrf-2 gene contributes to the pathogenesis of CAD, there are a number of possible explanations. First, the phenotypic change (ie, differentiation and dedifferentiation) of SMCs has recently been considered critical in the pathogenesis of atherosclerotic lesions. Since Mrf-2 was cloned as a key regulator for smooth muscle cell differentiation, 4) we hypothesized that Mrf-2 might be involved in the pathogenesis of atherosclerosis via its regulation of SMC differentiation. This question would be resolved by constructing a targeting mouse model of Mrf-2 and examining the changes of SMCs. Second, it was reported that mice lacking the Mrf-2 gene exhibited severe growth retardation, reduced weight gain, and reduced lipid accumulation, 8, 13, 14) which indicate the possibility that the association between Mrf-2 and CAD might be mediated partially through metabolic syndrome and DM. Third, Mrf-2 is a transcriptional factor which preferentially binds to the sequence AATAC/T and is expressed in the cardiovascular system. Thus, it is conceivable that this gene product might regulate other important vasoactive and pathogenetic molecules, which should be investigated in future studies. Fourth, Mrf-2 was shown to be an early marker for nephrogenic tissues, and broad expression of Mrf-2α was observed in lung, heart, brown adi-pose tissue, brain and kidney, which suggested widespread biological functions. Gene targeting of Mrf-2 indicated that the homozygous mutant showed reduced viability, displayed female and male reproductive organ abnormalities, and adrenal gland abnormalities, 8, 13) suggesting that Mrf-2 might presumably play important roles in the endocrine system through which it has an effect on the pathogenesis of CAD.
Overall, the present results demonstrate for the first time disease associations of the Mrf-2 SNPs with the presence of CAD. One limitation of the present study is the number of subjects studied. To validate the present findings, more individuals need to be recruited. In addition, much more basic research should be conducted to elucidate the mechanisms of the Mrf-2 gene. Furthermore, a prospective study would be a more effective means and should be performed to obtain reliable information on the clinical utility of this possible genetic risk factor of CAD.
